{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:57:46Z","timestamp":1783648666691,"version":"3.55.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.ctrv.2019.03.001","type":"journal-article","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T12:06:05Z","timestamp":1552305965000},"page":"20-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Aggressive variants of prostate cancer \u2013 Are we ready to apply specific treatment right now?"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5107-3523","authenticated-orcid":false,"given":"Igor","family":"Tsaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Heidegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kretschmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Borgmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Gandaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"de Visschere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Valerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick","family":"van den Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Ost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Mirvald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3799-4988","authenticated-orcid":false,"given":"Guillaume","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Surcel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2019.03.001_b0005","first-page":"7","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA: Cancer J Clin"},{"key":"10.1016\/j.ctrv.2019.03.001_b0010","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/annonc\/mdv257","article-title":"Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015","volume":"26","author":"Gillessen","year":"2015","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2019.03.001_b0015","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"New England J Med"},{"key":"10.1016\/j.ctrv.2019.03.001_b0020","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"New England J Med"},{"key":"10.1016\/j.ctrv.2019.03.001_b0025","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/sj.bjc.6603223","article-title":"Improving the outcome of patients with castration-resistant prostate cancer through rational drug development","volume":"95","author":"Attard","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2019.03.001_b0030","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"New England J Med"},{"key":"10.1016\/j.ctrv.2019.03.001_b0035","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"New England J Med"},{"key":"10.1016\/j.ctrv.2019.03.001_b0040","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"New England J Med"},{"key":"10.1016\/j.ctrv.2019.03.001_b0045","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1158\/1078-0432.CCR-13-3309","article-title":"Aggressive variants of castration-resistant prostate cancer","volume":"20","author":"Beltran","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2019.03.001_b0050","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","article-title":"Platinum-based chemotherapy for variant castrate-resistant prostate cancer","volume":"19","author":"Aparicio","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2019.03.001_b0055","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1016\/S0022-5347(05)65024-0","article-title":"Metastatic carcinoid tumor of the prostate","volume":"167","author":"Tash","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2019.03.001_b0060","first-page":"4145","article-title":"Contemporary incidence and mortality rates of neuroendocrine prostate cancer","volume":"35","author":"Alanee","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2019.03.001_b0065","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.juro.2007.05.044","article-title":"Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers","volume":"178","author":"Culine","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2019.03.001_b0070","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/iju.13526","article-title":"Clinical and molecular features of treatment-related neuroendocrine prostate cancer","volume":"25","author":"Akamatsu","year":"2018","journal-title":"Int J Urol: Off J Jpn Urol Assoc"},{"key":"10.1016\/j.ctrv.2019.03.001_b0075","article-title":"Aggressive variant and treatment-related neuroendocrine prostate cancer: two different terms for the same disease?","author":"Tsaur","year":"2018","journal-title":"Memo \u2013 Mag Eur Med Oncol"},{"key":"10.1016\/j.ctrv.2019.03.001_b0080","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/PAS.0000000000000208","article-title":"Proposed morphologic classification of prostate cancer with neuroendocrine differentiation","volume":"38","author":"Epstein","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2019.03.001_b0085","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11912-017-0593-6","article-title":"Emerging variants of castration-resistant prostate cancer","volume":"19","author":"Vlachostergios","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ctrv.2019.03.001_b0090","doi-asserted-by":"crossref","first-page":"193-","DOI":"10.1200\/JCO.2018.36.6_suppl.193","article-title":"Influence of aggressive-variant prostate cancer (AVPC) features on outcome of metastatic hormone-sensitive prostate cancer (mHSPC) treated by chemohormonal therapy (CHT)","volume":"36","author":"Koczka","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.03.001_b0095","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-2559.2011.04039.x","article-title":"Histological variants of prostatic carcinoma and their significance","volume":"60","author":"Humphrey","year":"2012","journal-title":"Histopathology"},{"key":"10.1016\/j.ctrv.2019.03.001_b0100","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/j.1464-410X.2008.08074.x","article-title":"Rare and unusual histological variants of prostatic carcinoma: clinical significance","volume":"102","author":"Mazzucchelli","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.ctrv.2019.03.001_b0105","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-15-1259","article-title":"Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers","volume":"22","author":"Aparicio","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2019.03.001_b0110","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.bbcan.2018.06.006","article-title":"EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers","volume":"1870","author":"Soundararajan","year":"2018","journal-title":"Biochim Biophys Acta, Rev Cancer"},{"key":"10.1016\/j.ctrv.2019.03.001_b0115","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/pros.20910","article-title":"Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate","volume":"69","author":"Hansel","year":"2009","journal-title":"Prostate"},{"key":"10.1016\/j.ctrv.2019.03.001_b0120","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1677\/erc.0.0060503","article-title":"Neuroendocrine cells in tumour growth of the prostate","volume":"6","author":"Abrahamsson","year":"1999","journal-title":"Endocr Relat Cancer"},{"issue":"265","key":"10.1016\/j.ctrv.2019.03.001_b0125","first-page":"e1","article-title":"Prognostic effect of neuroendocrine differentiation in prostate cancer: a critical review","volume":"33","author":"Surcel","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ctrv.2019.03.001_b0130","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.juro.2007.05.018","article-title":"Chromogranin A expression in patients with hormone naive prostate cancer predicts the development of hormone refractory disease","volume":"178","author":"Berruti","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2019.03.001_b0135","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"Guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2019.03.001_b0140","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1442-2042.2008.02175.x","article-title":"Neuroendocrine differentiation in the progression of prostate cancer","volume":"16","author":"Komiya","year":"2009","journal-title":"Int J Urol: Off J Jpn Urol Assoc"},{"key":"10.1016\/j.ctrv.2019.03.001_b0145","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0022-5347(05)64626-5","article-title":"Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival","volume":"168","author":"Bostwick","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2019.03.001_b0150","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18081640","article-title":"Neuroendocrine differentiation in metastatic conventional prostate cancer is significantly increased in lymph node metastases compared to the primary tumors","volume":"18","author":"Genitsch","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2019.03.001_b0155","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00000478-199201000-00009","article-title":"Paneth cell-like change of the prostate gland. A histological, immunohistochemical, and electron microscopic study","volume":"16","author":"Weaver","year":"1992","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2019.03.001_b0160","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/00000478-200608000-00008","article-title":"Prognostic significance of paneth cell-like neuroendocrine differentiation in adenocarcinoma of the prostate","volume":"30","author":"Tamas","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2019.03.001_b0165","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0046-8177(94)90268-2","article-title":"Paneth cell-like change in prostatic adenocarcinoma represents neuroendocrine differentiation: report of 30 cases","volume":"25","author":"Adlakha","year":"1994","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ctrv.2019.03.001_b0170","first-page":"148","article-title":"Neuroendocrine differentiation in prostate cancer","volume":"1","author":"Sun","year":"2009","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.ctrv.2019.03.001_b0175","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/00000478-200606000-00005","article-title":"Small cell carcinoma of the prostate: an immunohistochemical study","volume":"30","author":"Yao","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2019.03.001_b0180","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.1117679","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2019.03.001_b0185","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/modpathol.2011.7","article-title":"ERG gene rearrangements are common in prostatic small cell carcinomas","volume":"24","author":"Lotan","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2019.03.001_b0190","article-title":"Lineage plasticity-mediated therapy resistance in prostate cancer","author":"Blee","year":"2018","journal-title":"Asian J Androl"},{"key":"10.1016\/j.ctrv.2019.03.001_b0195","first-page":"473","article-title":"Implication of cell kinetic changes during the progression of human prostatic cancer","volume":"1","author":"Berges","year":"1995","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2019.03.001_b0200","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1210\/me.2003-0031","article-title":"Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells","volume":"17","author":"Wright","year":"2003","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.ctrv.2019.03.001_b0205","first-page":"1221","article-title":"Up-regulation of neuroendocrine differentiation in prostate cancer after androgen deprivation therapy, degree and androgen independence","volume":"8","author":"Ito","year":"2001","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ctrv.2019.03.001_b0210","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1677\/ERC-07-0061","article-title":"Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells","volume":"14","author":"Yuan","year":"2007","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ctrv.2019.03.001_b0215","first-page":"1549","article-title":"Activation of the Erk mitogen-activated protein kinase pathway stimulates neuroendocrine differentiation in LNCaP cells independently of cell cycle withdrawal and STAT3 phosphorylation","volume":"62","author":"Kim","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2019.03.001_b0220","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.celrep.2015.07.012","article-title":"The placental gene PEG10 promotes progression of neuroendocrine prostate cancer","volume":"12","author":"Akamatsu","year":"2015","journal-title":"Cell Reports"},{"key":"10.1016\/j.ctrv.2019.03.001_b0225","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1158\/1078-0432.CCR-14-1358","article-title":"Novel actions of next-generation taxanes benefit advanced stages of prostate cancer","volume":"21","author":"de Leeuw","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2019.03.001_b0230","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.eururo.2016.04.028","article-title":"SRRM4 drives neuroendocrine transdifferentiation of prostate adenocarcinoma under androgen receptor pathway inhibition","volume":"71","author":"Li","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2019.03.001_b0235","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrurol.2014.21","article-title":"Small cell carcinoma of the prostate","volume":"11","author":"Nadal","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ctrv.2019.03.001_b0240","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/PAS.0b013e318058a96b","article-title":"Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases","volume":"32","author":"Wang","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2019.03.001_b0245","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/cncr.22971","article-title":"Treatment outcomes of small cell carcinoma of the prostate: a single-center study","volume":"110","author":"Spiess","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2019.03.001_b0250","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/(SICI)1097-0045(199602)28:2<98::AID-PROS4>3.0.CO;2-J","article-title":"Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model","volume":"28","author":"Bonkhoff","year":"1996","journal-title":"Prostate"},{"key":"10.1016\/j.ctrv.2019.03.001_b0255","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1530\/ERC-11-0368","article-title":"Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway","volume":"19","author":"Chen","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ctrv.2019.03.001_b0260","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/S0022-5347(05)68241-9","article-title":"Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo","volume":"162","author":"Burchardt","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2019.03.001_b0265","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/mc.22162","article-title":"Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma","volume":"54","author":"Wang","year":"2015","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.ctrv.2019.03.001_b0270","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cllc.2011.03.002","article-title":"History of small-cell lung cancer","volume":"12","author":"Haddadin","year":"2011","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2019.03.001_b0275","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I","article-title":"Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms","volume":"68","author":"Moertel","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2019.03.001_b0280","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0090-4295(92)90235-O","article-title":"Small cell carcinoma of prostate: effectiveness of hormonal versus chemotherapy","volume":"39","author":"Moore","year":"1992","journal-title":"Urology"},{"key":"10.1016\/j.ctrv.2019.03.001_b0285","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1080\/028418602321028292","article-title":"Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements","volume":"41","author":"Steineck","year":"2002","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2019.03.001_b0290","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0022-5347(17)37427-X","article-title":"Chemotherapy for small cell carcinoma of prostatic origin","volume":"147","author":"Amato","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2019.03.001_b0295","article-title":"A phase II trial of the aurora kinase A inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers","author":"Beltran","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2019.03.001_b0300","doi-asserted-by":"crossref","first-page":"5010-","DOI":"10.1200\/jco.2015.33.15_suppl.5010","article-title":"A multi-institutional randomized phase II study (NCT01505868) of cabazitaxel (CAB) plus or minus carboplatin (CARB) in men with metastatic castration-resistant prostate cancer (mCRPC)","volume":"33","author":"Corn","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.03.001_b0305","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1093\/annonc\/mdr004","article-title":"Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial","volume":"22","author":"Flechon","year":"2011","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctrv.2019.03.001_b0310","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1200\/JCO.2002.12.065","article-title":"Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate","volume":"20","author":"Papandreou","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.03.001_b0315","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/j.1464-410X.2006.06041.x","article-title":"Genitourinary small cell carcinoma: a retrospective review of treatment and survival patterns at The Ottawa Hospital Regional Cancer Center","volume":"97","author":"Asmis","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.ctrv.2019.03.001_b0320","doi-asserted-by":"crossref","first-page":"5013-","DOI":"10.1200\/JCO.2017.35.15_suppl.5013","article-title":"The aggressive variant prostate carcinoma (AVPC) molecular signature (-MS) and platinum-sensitivity in castration resistant prostate cancer (CRPC)","volume":"35","author":"Aparicio","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.03.001_b0325","doi-asserted-by":"crossref","first-page":"17","DOI":"10.18632\/oncotarget.26523","article-title":"Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate","volume":"10","author":"Apostolidis","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2019.03.001_b0330","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4103\/0972-3919.125760","article-title":"PET\/CT imaging of neuroendocrine tumors with (68)Gallium-labeled somatostatin analogues: an overview and single institutional experience from India","volume":"29","author":"Sharma","year":"2014","journal-title":"Indian J Nucl Med"},{"key":"10.1016\/j.ctrv.2019.03.001_b0335","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/RLU.0000000000001419","article-title":"68Ga-DOTATOC and 68Ga-PSMA PET\/CT unmasked a case of prostate cancer with neuroendocrine differentiation","volume":"41","author":"Chen","year":"2016","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.ctrv.2019.03.001_b0340","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/RLU.0000000000001618","article-title":"Molecular imaging in neuroendocrine differentiation of prostate cancer: 68Ga-PSMA versus 68Ga-DOTA NOC PET-CT","volume":"42","author":"Usmani","year":"2017","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.ctrv.2019.03.001_b0345","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/0959-8049(94)90455-3","article-title":"Activity of docetaxel (Taxotere) in small cell lung cancer. The early clinical trials group of the EORTC","volume":"30A","author":"Smyth","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2019.03.001_b0350","first-page":"237","article-title":"Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trial","volume":"5","author":"Hesketh","year":"1999","journal-title":"Cancer J Sci Am"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737219300490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737219300490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:20:04Z","timestamp":1759656004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737219300490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":70,"alternative-id":["S0305737219300490"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2019.03.001","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aggressive variants of prostate cancer \u2013 Are we ready to apply specific treatment right now?","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2019.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}